Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) | Progressive Metastatic Castrate Resistant Prostate Cancer | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07206056 | |
| Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors | Carcinoma, Medullary, DNA Virus Infections, Infections, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Thoracic Neoplasms, Tumor Virus Infections, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cutaneous neuroendocrine carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, medullary thyroid gland carcinoma, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, polyomavirus infectious disease, primitive neuroectodermal tumor, pulmonary large cell neuroendocrine carcinoma, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma, thymic neuroendocrine carcinoma, viral infectious disease | Recruiting | Phase 1 | 2026-09-22 | NCT07006727 | |
| Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-22 | NCT06780670 | |
| A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Not stated | 2026-07-20 | NCT07091019 |